What is the current Price Target for the Neumora Therapeutics stock?

The average Neumora Therapeutics target price is $5.10. This is 598.63% higher than the current stock price. The highest price target is 1,913.70%, the lowest is 315.07%. 9 Analysts have issued a price target Neumora Therapeutics 2027 .

How high will the Neumora Therapeutics stock rise?

No reliable answer can be given as to how high the Neumora Therapeutics stock will rise. The performance of stocks, including the Neumora Therapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Neumora Therapeutics stock today?

The performance of Neumora Therapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Neumora Therapeutics stock fall?

The decline in Neumora Therapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Neumora Therapeutics Forecast, price target & analysts

$0.73

2.67%

Nasdaq, Sep 18, 04:00 pm EDT. Closed.

ISIN

US6409791000

Symbol

NMRA

Reports

Quarter | Annual

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Analysts Charts Ownership News Strategies

Neumora Therapeutics Target price 2026 - Analyst rating & recommendation

Neumora Therapeutics Classifications & Recommendation

Buy

80%

Hold

13%

Sell

Neumora Therapeutics Price Target

Target Price	$5.10
Price	$0.73
Potential	598.63% register free of charge
Number of Estimates	9

	9 Analysts have issued a price target Neumora Therapeutics 2027 . The average Neumora Therapeutics target price is $5.10. This is 598.63% register free of charge higher than the current stock price. The highest price target is $14.70 1,913.70% register free of charge , the lowest is $3.03 315.07% register free of charge .
	A rating was issued by 15 analysts: 12 Analysts recommend Neumora Therapeutics to buy, 2 to hold and 1 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Neumora Therapeutics stock has an average upside potential 2027 of 598.63% register free of charge . Most analysts recommend the Neumora Therapeutics stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '25	2026 Estimates
Earnings Per Share $	-1.45	-0.89
	5.23%	38.62%
P/E		negative

11 Analysts have issued a Neumora Therapeutics forecast for earnings per share. The average Neumora Therapeutics EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2025. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2025	$-1.45	5.23%
2026	$-0.89 38.62% unlock
2027	$-0.74 16.85% unlock
2028	$-0.75 1.35% unlock
2029	$-0.56 25.33% unlock
2030	$0.00 100.00% unlock
2032	$2.82 69.88% unlock
2033	$4.81 70.57% unlock

Current	-0.64	37.93%
2026	-0.82 28.04% unlock
2027	-0.98 19.51% unlock
2028	-0.98 0.00% unlock
2029	-1.31 33.67% unlock
2030	178.92 13,758.02% unlock
2031	0.44 99.75% unlock
2032	0.26 40.91% unlock
2033	0.15 42.31% unlock

Neumora Therapeutics...

Current Neumora Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
RBC Capital	Locked ➜ Locked	Locked	Jul 13 2026
Mizuho	Locked ➜ Locked	Locked	Jun 18 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jun 16 2026
Needham	Locked ➜ Locked	Locked	Jun 16 2026
Guggenheim	Locked ➜ Locked	Locked	Mar 31 2026
Needham	Locked ➜ Locked	Locked	Mar 31 2026
William Blair	Locked ➜ Locked	Locked	Feb 17 2026

Analyst Rating	Date
Locked RBC Capital: Locked ➜ Locked	Jul 13 2026
Locked Mizuho: Locked ➜ Locked	Jun 18 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	Jun 16 2026
Locked Needham: Locked ➜ Locked	Jun 16 2026
Locked Guggenheim: Locked ➜ Locked	Mar 31 2026
Locked Needham: Locked ➜ Locked	Mar 31 2026
Locked William Blair: Locked ➜ Locked	Feb 17 2026

Discover more stocks with a high price target

NIO ADR 100.10%

Alibaba Group Holding Ltd 68.75%

Infineon 65.25%

Tencent Holdings Ltd. 63.10%

Rheinmetall 61.30%

TUI 56.70%

Adyen 53.16%

Siemens Energy 49.14%

Adidas 46.64%

Uber Technologies 46.13%

BYD 40.95%

NVIDIA 37.67%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now